Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Neurofibromatoses
- Focus Therapeutic Use
- Acronyms DCLNF1
- 10 Jun 2017 Biomarkers information updated
- 11 May 2016 Status changed from recruiting to completed.
- 25 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.